



Cohort Profile

Cohort profile: Early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II) database

Rachel H. Mulholland ¹, **Eleftheria Vasileiou**,^{1*} **Colin R. Simpson**,^{1,2} **Chris Robertson**,^{3,4} **Lewis D. Ritchie**,⁵ **Utkarsh Agrawal**,⁶ **Mark Woolhouse**,¹ **Josephine L.K. Murray**,⁴ **Helen R. Stagg**,¹ **Annemarie B. Docherty**,¹ **Colin McCowan** ⁶, **Rachael Wood**,^{1,4} **Sarah J. Stock**¹ and **Aziz Sheikh**¹

¹Usher Institute, University of Edinburgh, Edinburgh, UK, ²School of Health, Wellington Faculty of Health, Victoria University of Wellington, Wellington, New Zealand, ³Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK, ⁴Public Health Scotland, Glasgow and Edinburgh, UK, ⁵Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK, ⁶School of Medicine, University of St Andrews, St Andrews, UK

*Corresponding author. Usher Institute, University of Edinburgh, NINE Edinburgh BioQuarter, Edinburgh EH16 4UX, UK.
E-mail: eleftheria.vasileiou@ed.ac.uk

Editorial decision 29 January 2021; Accepted 19 February 2021

Why was the cohort set up?

In December 2019, a novel coronavirus COVID-19 emerged from Wuhan, China, and was soon declared as pandemic by the World Health Organization (WHO) on the 11 March 2020.¹ The UK soon followed suit and implemented a national lockdown on the 23 March 2020. As of 9 December 2020, according to WHO, this highly infectious virus has infected more than 67 million people and led to over 1.5 million deaths across the world.² There is a growing body of evidence on the epidemiology of the condition, risk factors for poor outcomes and effects of interventions.^{3–9}

The rapid generation of robust data is crucial to monitor, understand and mitigate the effects of COVID-19. The Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) database creates a national, real-time prospective cohort using Scotland's health data infrastructure, to describe the epidemiology of COVID-19 infection, patterns of healthcare use and outcomes, and

insights into the effectiveness of and safety of vaccines and treatments for COVID-19.¹⁰

This work builds on an established cohort for seasonal and pandemic influenza vaccine and anti-viral assessment in Scotland EAVE (Early Estimation of Vaccine and Anti-Viral Effectiveness).^{11,12} EAVE is a dormant pandemic protocol that is part of the National Institute for Health Research (NIHR) Pandemic Preparedness Research Portfolio and a platform for previous studies on influenza vaccine and antiviral assessment.^{12–16}

Who is in the cohort?

We obtained ethical approval from the National Research Ethics Service Committee, Southeast Scotland 02.

This prospective baseline cohort study contains all 5.4 million individuals registered with a general practitioner (GP) in Scotland from 23 February 2020 which, according to the National Records of Scotland (NRS) 2019 mid-year

estimates, covers around 98–99% of the Scottish population.^{10,17} A map of the baseline EAVE II cohort by the National Health Service (NHS) Health Board shows that most of the cohort are based in the central belt of Scotland (Figure 1).

A summary of the baseline population by sex, age group (as of 23 February) and deprivation used the Scottish Index of Multiple Deprivation (SIMD)¹⁸ and Scottish Government Urban Rural Classification.¹⁹ SIMD is a measure of deprivation built on seven domains and is unique to Scotland, with lower quintiles representing the most deprived areas.¹⁸

These primary care records are linked to other data sources from out-of-hours, emergency and secondary care. There are additional linkages to other datasets such as laboratory testing data, registration and mortality data, self-reported data and enhanced surveillance data such as the COVID-19 Clinical Information Network (CO-CIN). This is done using the Community Health Index (CHI), the unique identifier provided by NHS Scotland. It is allocated to all residents in Scotland registered with a GP and to all patients who receive care in Scotland, even if they are non-Scottish residents.¹⁰ Summaries of these data sources are given in Table 2, with a data flow diagram on how they are linked together in Figure 2.




Figure 1 Baseline Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) cohort population by National Health Service (NHS) Health Board. (1=NHS Ayrshire and Arran; 2=NHS Borders; 3=NHS Dumfries and Galloway; 4=NHS Forth Valley; 5=NHS Grampian; 6=NHS Highland; 7=NHS Lothian; 8=NHS Orkney; 9=NHS Shetland; 10=NHS Western Isles; 11=NHS Fife; 12=NHS Tayside; 13=NHS Greater Glasgow and Clyde; 14=NHS Lanarkshire ordered by Health board code).

This cohort therefore consists of specific groups of interest that are used in EAVE II sub-studies such as the COVID-19 in Pregnancy in Scotland (COPS)³⁷ and for investigating ethnic and social inequalities in COVID-19.

How often have they been followed up?

The baseline GP records will be updated on a biannual to 3-monthly basis, if possible. The first update in early 2021 will contain COVID-19-specific GP codes that were created during the pandemic and were therefore missed in the initial extract. This will capture information on COVID-19 related appointments, vaccinations, therapies and vaccination-induced adverse effects. Information on influenza will also be included to facilitate analyses on the effectiveness of and safety of COVID-19-specific and pre-existing vaccines, therapies and treatments. To facilitate

Table 1 Baseline characteristics of the population in the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) cohort study ($n = 5\,431\,034$). Update: 23 February 2020

Characteristics	Total number of individuals (% of total)
Sex	
Female	2733477 (50.3)
Male	2697557 (49.7)
Age group (years)	
0–4	245423 (4.5)
5–14	574389 (10.6)
15–24	624070 (11.5)
25–44	1479594 (27.2)
45–64	1503617 (27.7)
65–74	563605 (10.4)
75–84	323812 (6.0)
>85	116524 (2.1)
Deprivation quintile ^a	
1: most deprived	1100521 (20.3)
2	1074842 (19.8)
3	1050369 (19.3)
4	1079282 (19.9)
5: least deprived	1080775 (19.9)
Urban/rural score ^b	
1: large urban areas	1920932 (35.4)
2: other urban areas	1959281 (36.1)
3: accessible small towns	501557 (9.2)
4: remote small towns	257264 (4.7)
5: accessible rural	486665 (9.0)
6: remote rural	260090 (4.8)

Missing values (%) as below.

^aDeprivation score not available for 45 245 (0.8%) individuals. Score calculated via the Scottish Index of Multiple Deprivation (SIMD).

^bUrban/rural score not available for 45 245 (0.8%) individuals.

^cNHS Health Board not available for 45 245 (0.8%) individuals.

Table 2 Details of data sources within the different settings for the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) cohort

Setting	Data sources	Description
Primary care	General practice (GP) data ^a	Data from all patients registered with GP. GP data (demographic, consultation data—categorized into risk groups, prescribing and categorized measurements) will be extracted using the Enhanced Services Contract Reporting Options (ESCRO) system by the trusted third party Albasoft Ltd ¹⁰
	Prescribing Information System (PIS) ^a	Information on all prescribing relating to all prescriptions dispensed in the community. Prescriptions written in hospitals which are dispensed in the community are also included ²⁰
	Out-of-hours (OOH) ^b	Data on the services a patient receives for primary care when their registered GP practice is closed ²¹
Telephone consultation	Scottish Morbidity Record 00 (SMR00) ^a	Relates to all outpatients (new and follow-up) in specialties other than Accident & Emergency (A&E), and Genito-urinary Medicine ²²
	National Health Service (NHS) 24 ^a	Delivers telephone and online services across Scotland for initial assessments, which are then passed on to the appropriate services if required ¹⁰
Secondary care	COVID-19 Community Hubs and Assessment Centres ^b	A network established by NHS Health Boards in Scotland to provide a direct and rapid route of people with COVID-19 ¹⁰ . Data from these centres will derive from National Health Service (NHS) 24 and the COVID-19 Enhanced Surveillance dataset ¹⁰ .
	Scottish Morbidity Record (SMR) including: SMR01 ^a SMR02 ^a	SMR01: Episode-based patient record for all inpatients and day cases discharged from non-obstetric and non-psychiatric specialties in Scotland. This includes Accident & Emergency (A&E) attendances ¹⁰ SMR02: Episode-based patient record for all inpatients and day cases discharged from obstetric specialties in Scotland ¹⁰
	Scottish Hospital Electronic Prescribing and Medicines Administration (HEMPA) system ^a	Data on prescription and administration of medicines for inpatients from a subgroup of hospitals with HEPMA systems ¹⁰
	Scottish Ambulance Service (SAS) ^a	Scottish database for all patients requiring emergency ambulance services or needing support to reach their health care appointments due to their medical and mobility needs ²³
	Scottish Intensive Care Society Audit Group (SICSAG) ^a	Scottish database for adult patients admitted to all general intensive care units (ICU) and combined ICU/high dependency units (HDU) ¹⁰
	COVID19 Clinical Information Network/International Severe Acute Respiratory and emerging Infection Consortium (CO-CIN/ISARIC) ^p	Data of the clinical characteristics of patients admitted to hospital with COVID-19 infection in Scotland recruited to CO-CIN/ISARIC. ²⁴ As of 22 June 2020 this comprised 65% of the hospitalized patients in Scotland
	Rapid Preliminary Inpatient Data (RAPID) ^b	Contains hospital inpatient admission data which have been used to predict emergency admissions and bed occupancy ²⁵
Mortality data	National Records of Scotland (NRS) deaths ^a	Data on Scottish death certificates and the cause of death ²⁶
Laboratory and serology data	Electronic Communication of Surveillance in Scotland (ECOSS) ^a	Surveillance data on laboratory results from microorganisms, infections and microbial intoxications. Contains all reverse transcriptase polymerase chain reaction (RT-PCR) tests carried out in Scotland ¹⁰
	Serology data ^a	All serology data will be provided by the ‘Seroprevalence’ work carried out and commissioned by the COVID-19 Enhanced Surveillance cell of Public Health Scotland (PHS) ¹⁰
	Genome sequencing data ^b	Positive laboratory RT-PCR swab samples for COVID-19 will also be sent to national sequencing centres where 500 COVID-19 genome sequences will be performed ¹⁰

(Continued)

Table 2 Continued

Setting	Data sources	Description
Self-reported data	Test and Protect data ^b	A service which identifies positive cases of COVID-19 and who they have had close, recent contact with ²⁷
	Surveys ^b	Surveys on how people have been affected by COVID-19 in Scotland
	Census 2011 data ^b	Residents in Scotland are asked to fill in a census questionnaire every 10 years and provide information on their demographic (e.g. ethnicity), socioeconomic, health and other circumstances. NRS will provide data from the latest Scottish Census in 2011 ²⁸
Derived data	COVID-19 shielding patient list ^b	Uses a combination of primary and secondary care held in Public Health Scotland to derive groups considered to be at high risk if they contract COVID-19 ²⁹
Births and pregnancy-related data	Scottish Birth Record (SBR) ^b	The SBR is a web-based system developed on the NHSNet to ensure that every baby born in Scotland will have one record which will act as the foundation for future information collection. The system has been implemented to varying degrees in all Scottish hospitals providing midwifery and/or neonatal care ³⁰
	NHS live birth notifications ^b	Notification of live births from NHS Board maternity units to child health administration departments ³¹
	NRS births ^b	Record of statutory registration of a live birth (live-born baby at any gestation) ³²
	NRS statutory stillbirth registrations ^b	Record of statutory registration of a stillbirth (baby born at ≥ 24 weeks, showing no signs of life) ³³
	NHS antenatal care notifications ^b	Public Health Scotland (PHS) has developed a new national data return as part of the response to the COVID-19 pandemic, providing information on women booking for antenatal care with NHS maternity services: for identification of women with ongoing pregnancies in near real-time
Vaccine treatment	Abortion Act Scotland (AAS) Notifications ^b	Record of statutory notification of all terminations of pregnancy in Scotland ³⁴
	Child Health Systems Programme—School (CHSP-S) ^a	Facilitates the call/recall of both primary and secondary school pupils for screening, review and immunization ³⁵
	Scottish Immunisation Recall System (SIRS) ^b	Data on recorded immunization in children when scheduled for a vaccination, including children of pre-school age ³⁶

HEPMA, Hospital Electronic Prescribing and Medicines Administration.

^aData sources approved as of May 2020.

^bData sources pursuing.

UK-wide research, QCOVID groups will also be added to allow validation of the QCOVID ‘living’ risk prediction model on the Scottish population.³⁸ Information on shielded risk groups will also be included to assess the impact of COVID-19 on those most at risk for severe illness where a 12-month self-isolation was recommended by the UK government on 23 March 2020.³⁹

Regular updates on a number of linked datasets and the underlying GP data will be undertaken on a daily, weekly or monthly basis, as available and necessary (see [Table 3](#)). Those who have transferred GPs within Scotland will stay in the cohort. Participants who die or permanently leave Scotland (and deregister from general practices) will drop out of the cohort. Characteristics of individuals lost to follow-up compared with those remaining in the cohort will also be provided in the study. Missing data will also be reported for each variable.

What has been measured?

Combining these rich data sources together provides a wealth of information on the natural history of the condition and patients’ journeys across Scotland’s NHS. We provide a high-level summary of key available data in [Table 4](#).

What has it found?

Permissions to link these datasets were received in May 2020 and the flow of linked data began in June 2020. The initial GP data extract contained the baseline cohort and the EAVE II risk groups, which were based on the risk groups for seasonal influenza, as research at the time of extract did not know exact risk groups for COVID-19. This includes comorbidities and household characteristics, for




Figure 2 Flow diagram for the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) cohort. Primary care consultations (SMR; Scottish Morbidity Record; OOH: Out-of-hours); Hospital Admission (SICSAG: Scottish Intensive Care Society Audit Group; CO-CIN: COVID19 Clinical Information Network; RAPID: Rapid Preliminary Inpatient Data; SAS: Scottish Ambulance Service); Prescribing (PIS: Prescribing Information System; HEMPA: Hospital Electronic Prescribing and Medicines Administration); Laboratory (ECOSS: Electronic Communication of Surveillance in Scotland; RT-PCR: Reverse transcription polymerase chain reaction); Vaccine Treatment (CHSP-S: Child Health Systems Programme School; SIRS: Scottish Immunisation Recall System); Birth and Pregnancy (SBR: Scottish Birth Record; NRS: National Records of Scotland; AAS: Abortion Act Scotland).

Table 3 Details on frequency of data linkages

Daily or weekly linkages	Weekly or monthly linkages	Monthly linkages
ECOSS	SMR01	SBR
NHS 24	SMR02	NRS births
SAS	PIS	NRS stillbirths
Serology data	NRS deaths	NHS antenatal care
SICSAG	CO-CIN	AAS
RAPID	OOH	

AAS, Abortion Act Scotland; CO-CIN, COVID-19 Clinical Information Network; ECOSS, Electronic Communication of Surveillance in Scotland; NHS, National Health Service; NRS, National Records of Scotland; OOH, Out-of-hours; PIS, Prescribing Information System; RAPID, Rapid Preliminary Inpatient Data; SAS, Scottish Ambulance Service; SBR, Scottish Birth Record; SICSAG, Scottish Intensive Care Society Audit Group; SMR, Scottish Morbidity Record.

example an indicator of living in a care home. This EAVE II risk group dataset contained more individuals than the baseline cohort, with over-representation in certain populations. This is likely to have resulted in residents being registered at multiple GP practices, people who have left Scotland or visitors. To overcome this, weights were calculated by comparing the age and sex profile in the EAVE II cohort with the age and sex profile for the 2019 NRS mid-year population estimates in Scotland.¹⁷ A summary of the number of EAVE II risk groups using these weights is shown in the [Supplementary material](#), along with the individual risk groups ([Supplementary Table S1](#), available as [Supplementary data](#) at *IJE* online). The following analyses were performed using these weights.

Initial explorations showed that as age increased, lower levels of deprivation using SIMD quintiles slightly

Table 4 Variables captured and their relevant data sources

Category	Variable group	Specific variables	Source(s)
COVID-19 outcomes	Testing	Tested; date of positive/negative test; test results; type of test; antibody tests (if available)	COVID-19 Community Hubs and Assessment Centres; ECOSS; serology data; genome sequencing data; Test and Protect data
	Severity	Severity; symptoms; hospital admission; admitted to ICU; treatment in ICU	NHS 24; COVID-19 Community Hubs and Assessment Centres; SMR; SAS; SICSAG; CO-CIN; RAPID; Test and Protect data; Surveys; SMR01; SMR00
	Mortality	Death; cause of death	NRS deaths; SMR
	Treatment	Type of vaccination; date of vaccination	GP data; ECOSS; CHSP-S; SIRS
Potential risk factors	Sociodemographic	Age; sex; ethnicity; country of birth; BMI; smoking; employment status; occupation; country of birth; religion; tenure	GP data; 2011 Census
	Geographical	Data zone; socioeconomic status (SES) through Scottish Multiple Deprivation Index (SIMD) ¹⁸ ; Urban Rural Index ¹⁹ ; pollution exposure ⁴⁰ ; population density	GP data (use postcode to link to relevant datasets)
	Clinical	Comorbidities including chronic respiratory disease (with chronic obstructive pulmonary disease and asthma as subsets); chronic heart disease; chronic liver disease; chronic kidney disease; chronic neurological disease; diabetes types 1 and 2; conditions or medications causing impaired immune function; pregnancy; asplenia or dysfunction of spleen; obesity; hypertension (subsets controlled/uncontrolled hypertension); tuberculosis; multimorbidity; Charlson Comorbidity Index	GP data; SMR
	Medications	Prescription drugs including asthma (including GINA management steps and oral steroids) and COPD-related prescriptions; regular inhalers; COVID/pandemic acute therapies and chronic therapy for long-term sequelae; statins; rhinitis therapy; immunotherapy; diabetes therapy; cardiovascular disease therapy; antihypertensives; antibiotics; NSAIDs; Cox2; paracetamol; antiviral prescriptions; drugs for previous primary care consultations; polypharmacy; high-risk prescribing	GP data; PIS; HEPMA
	Pregnancy and babies	Pregnancy indicator; miscarriage, ectopic pregnancy, pregnancy termination (incl. date, gestation, grounds); stillbirth (incl. date, gestation, cause of death); live birth (incl. date, gestation, sex of baby); congenital anomaly flag; neonatal outcomes following maternal infection	GP data; SMR; SICSAG; CO-CIN; SBR; NHS live birth; NRS births; NRS stillbirths; NHS antenatal care; AAS

AAS, Abortion Act Scotland; CO-CIN, COVID-19 Clinical Information Network; ECOSS, Electronic Communication of Surveillance in Scotland; ICU, intensive care unit; NHS, National Health Service; NRS, National Records of Scotland; OOH, Out-of-hours; PIS, Prescribing Information System; RAPID, Rapid Preliminary Inpatient Data; SAS, Scottish Ambulance Service; SBR, Scottish Birth Record; SICSAG, Scottish Intensive Care Society Audit Group; SMR, Scottish Morbidity Record; NSAID, non-steroidal anti-inflammatory drug; incl., including; HEPMA, Hospital Electronic Prescribing and Medicines Administration.


increased and the number of risk groups increased (Figure 3). These did not differ substantially between sexes (Figure 3).

Since the first follow-up of COVID-19 outcomes from 1 March to 10 November, there have been a total of 835 803 (15.4%) tested, 57 416 (1.1%) with a positive test (out of the total cohort), 9847 (0.2%) hospitalized with COVID-19, 5350 (0.1%) admitted to an intensive care unit (ICU) or died with COVID-19 on the death certificate and 4726 (0.1%) who have died with COVID-19 on the death certificate within the EAVE II cohort. The proportions of these outcomes split by age and sex for the same

time period show that more elderly residents have been tested with a resulting positive test (Figure 4). Elderly residents, particularly males, are also more represented in the more severe outcomes (Figure 4).

These age profiles were repeated for deprivation levels (using SIMD quintiles), the number of risk groups and the 20 most frequent individual risk groups within the EAVE II study (Supplementary material). This showed that there were higher proportions of positive tests and more severe outcomes in more deprived areas, residents belonging to multiple risk groups and those who had comorbidities

A SIMD Quintile



B Number of risk groups




Figure 3 Baseline Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) cohort population by National Health Service (NHS) Health Board. (1 = NHS Ayrshire and Arran; 2 = NHS Borders; 3 = NHS Dumfries and Galloway; 4 = NHS Forth Valley; 5 = NHS Grampian; 6 = NHS Highland; 7 = NHS Lothian; 8 = NHS Orkney; 9 = NHS Shetland; 10 = NHS Western Isles; 11 = NHS Fife; 12 = NHS Tayside; 13 = NHS Greater Glasgow and Clyde; 14 = NHS Lanarkshire ordered by Health board code).




Figure 4 Baseline Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) cohort population by National Health Service (NHS) Health Board. (1 = NHS Ayrshire and Arran; 2 = NHS Borders; 3 = NHS Dumfries and Galloway; 4 = NHS Forth Valley; 5 = NHS Grampian; 6 = NHS Highland; 7 = NHS Lothian; 8 = NHS Orkney; 9 = NHS Shetland; 10 = NHS Western Isles; 11 = NHS Fife; 12 = NHS Tayside; 13 = NHS Greater Glasgow and Clyde; 14 = NHS Lanarkshire ordered by Health board code).

([Supplementary material](#), available as [Supplementary data](#) at *IJE* online).

The map of the proportion of these outcomes by NHS Health Board demonstrated that despite high rates of testing in more rural areas in the northern and southern parts of Scotland, positive tests were low ([Figure 5](#)). The central belt had a higher proportion of positive tests out of the total baseline population and higher rates of more severe COVID-19 outcomes ([Figure 5](#)).

All relevant R code scripts for the summary tables and figures will be made available on the EAVE II GitHub page [<https://github.com/EAVE-II>]. This will also contain a data dictionary for the entire EAVE cohort which will be updated when new updates and data linkages are made.

We are currently working on the development of a national risk prediction algorithm to identify risk factors for poor outcomes i.e. hospitalisation and death from COVID-19,¹⁰ and the validation of the QCOVID-19 algorithm.³⁸



Figure 5 Baseline Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) cohort population by National Health Service (NHS) Health Board. (1 = NHS Ayrshire and Arran; 2 = NHS Borders; 3 = NHS Dumfries and Galloway; 4 = NHS Forth Valley; 5 = NHS Grampian; 6 = NHS Highland; 7 = NHS Lothian; 8 = NHS Orkney; 9 = NHS Shetland; 10 = NHS Western Isles; 11 = NHS Fife; 12 = NHS Tayside; 13 = NHS Greater Glasgow and Clyde; 14 = NHS Lanarkshire ordered by Health board code).

What are the main strengths and weaknesses?

The EAVE II cohort will be widely generalizable to the Scottish population as it contains all individuals registered within GP practices in Scotland, with exception of homeless, itinerant or travelling groups, those in prison, those who are institutionalized due to mental health reasons and other reasons. Regularly updating and monitoring this cohort over a long period of time will also be quick and cost effective as the underlying data sources are mainly routinely collected, quality assured and easily linkable using unique CHI numbers. This in turn means insights can be kept up to date with the rapidly evolving pandemic situation. The completeness and coverage, in terms of both population and breadth of data, are also a major strength.

The key limitations are the possibility of some selection biases because of excluded patients, although this is

estimated to be under 2% of the Scottish population, and the risk of residual confounding in the context of analytical epidemiological studies. Considerable care will need to be taken when making inferences about the effectiveness of interventions, because of non-randomized comparisons.

Can I get hold of the data? Where can I find out more?

Data can be accessed by contacting the corresponding author. For more information on the cohort, refer to the published EAVE II protocol.¹⁰ The study findings will be presented at international conferences and published in peer-reviewed journals.

Supplementary Data

Supplementary data are available at *IJE* online.

Profile in a nutshell

- The Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) database creates a national, real-time prospective cohort using Scotland's health data infrastructure, to describe the epidemiology of COVID-19, patterns of health care use and outcomes, and insights into the effectiveness and safety of vaccines and treatments for COVID-19. As far as we are aware, EAVE II is the first national end-to-end clinical surveillance platform for COVID-19 predominantly using routinely available data.
- This study contains all 5.4 million individuals registered with a GP in Scotland from 23 February 2020, covering 98–99% of the Scottish population. These primary care records are linked to other data sources from out-of-hours, community, emergency and secondary care, in addition to data on registrations and mortality, laboratory testing, self-report and enhanced surveillance.
- These data will be updated throughout the course of the pandemic. Participants who die or permanently leave Scotland (and deregister from general practices) will drop out of the cohort.
- Combining these rich data sources together provides a wealth of information on the natural history of the condition and patients' journeys across Scotland's National Health Service (NHS).
- Data will be hosted in Scotland's National Safe Haven within the electronic Data Research and Innovation Service (eDRIS) of Public Health Scotland (PHS). Applicants must submit an enquiry to the corresponding author.

Author Contributions

A.S. initiated the manuscript. R.H.M. and E.V. led the writing of the manuscript, and R.H.M. and C.R. led the analysis. All co-authors reviewed and contributed to the writing of the manuscript.

Funding

The original EAVE project was funded by the National Institute for Health Research Health Technology Assessment Programme (project number 13/34/14). EAVE II is funded by the Medical Research Council [MR/R008345/1] and supported by the Scottish Government. This work is supported by BREATHE—The Health Data Research Hub for Respiratory Health [MC_PC_19004]. BREATHE is funded through 10 the UK Research and Innovation

Industrial Strategy Challenge Fund and delivered through Health Data Research UK.

Conflict of interest

Details on competing interests are included in the study's protocol [<http://dx.doi.org/10.1136/bmjopen-2020-039097>]. Remaining co-authors (R.H.M., C.M., U.A., R.W., A.B.D., S.J.S.) do not report conflict of interest. A.D. and S.J.S. are also funded by Wellcome Trust Clinical Career Development. H.R.S. is supported by the Medical Research Council (MR/R008345/1).

References

1. World Health Organization. *Archived: WHO Timeline – COVID-19*. 2020. <https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19> (26 June 2020, date last accessed).
2. World Health Organization. *Coronavirus Disease (COVID-19) Outbreak*. 2020. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019> (26 June 2020, date last accessed).
3. Lancet. *COVID-19 Resource Centre*. 2020. <https://www.thelancet.com/coronavirus> (3 July 2020, date last accessed).
4. Oxford Academic. *Access to OUP Resources on COVID-19, Other Coronaviruses, and Related Topics*. <https://academic.oup.com/journals/pages/coronavirus> (3 July 2020, date last accessed).
5. Springer Nature. *COVID-19 and COVID-19*. https://www.springernature.com/gp/researchers/campaigns/coronavirus?utm_source=bmc&utm_medium=referral&utm_content=null&utm_campaign=Homepage_Coronavirus_Teaser (3 July 2020, date last accessed).
6. BMJ. *BMJ's Coronavirus (Covid-19) Hub*. <https://www.bmj.com/coronavirus> (3 July 2020, date last accessed).
7. PLOS. *COVID-19 Pandemic (2019–20)*. <https://collections.plos.org/covid-19> (3 July 2020, date last accessed).
8. JAMA Network. *Coronavirus Disease 2019 (COVID-19)*. https://jamanetwork.com/journals/jama/pages/coronavirus-alert?utm_campaign=COVID19&utm_medium=banner&utm_source=house&utm_content=leader&utm_term=728x90 (3 July 2020, date last accessed).
9. New England Journal of Medicine. *Coronavirus (Covid-19)*. <https://www.nejm.org/coronavirus> (3 July 2020, date last accessed).
10. Simpson CR, Robertson C, Vasileiou E *et al*. Early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II): protocol for an observational study using linked Scottish national data. *BMJ Open* 2020;**10**:e039097.
11. Simpson CR, Beever D, Challen K *et al*. The UK's pandemic influenza research portfolio: a model for future research on emerging infections. *Lancet Infect Dis* 2019;**19**:e295–e300.
12. Simpson CR, Lone N, McMenamin J *et al*. Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness (EAVE): use of a unique community and laboratory national data-linked cohort study. *Health Technol Assess* 2015;**19**:1–32.

13. Simpson CR, Ritchie LD, Robertson C *et al.* Vaccine effectiveness in pandemic influenza - primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine. *Health Technol Asses* 2010;14:313–46.
14. Simpson CR, Ritchie LD, Robertson C *et al.* Effectiveness of H1N1 vaccine for the prevention of pandemic influenza in Scotland, UK: a retrospective observational cohort study. *Lancet Infect Dis* 2012;12:696–702.
15. Simpson CR, Lone N, Kavanagh K *et al.* Seasonal Influenza Vaccine Effectiveness (SIVE): an observational retrospective cohort study – exploitation of a unique community-based national-linked database to determine the effectiveness of the seasonal trivalent influenza vaccine. *Health Services and Delivery Research* 2013;1:1–46.
16. Simpson CR, Lone NI, Kavanagh K *et al.* Evaluating the effectiveness, impact and safety of live attenuated and seasonal inactivated influenza vaccination: protocol for the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study. *BMJ Open* 2017;7:e014200.
17. National Records of Scotland (NRS). *Mid-2019 Population Estimates Scotland*. 2019. <https://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/population/population-estimates/mid-year-population-estimates/mid-2019> (June 23, 2020, date last accessed)
18. Scottish Government. *Scottish Index of Multiple Deprivation 2020*. <https://www.gov.scot/collections/scottish-index-of-multiple-deprivation-2020/> (June 11, 2020, date last accessed).
19. Scottish Government. *Scottish Government Urban Rural Classification 2016*. <https://www.gov.scot/publications/scottish-government-urban-rural-classification-2016/pages/6/> (June 11, 2020, date last accessed).
20. NHS National Services Scotland. *National Data Catalogue. Prescribing Information System (PIS)*. <https://www.ndc.scot.nhs.uk/National-Datasets/data.asp?SubID=9#Skip-Navigation> (10 June 2020, date last accessed).
21. Public Health Scotland. Data and Intelligence. *Primary Care Out of Hours Services. Emergency Care*. <https://www.isdscotland.org/Health-Topics/Emergency-Care/GP-Out-of-Hours-Services/> (23 June 2020, date last accessed).
22. ISD Scotland Home. *Data Dictionary A-Z. SMR00 – Outpatient Attendance*. <https://www.ndc.scot.nhs.uk/Dictionary-A-Z/Definitions/index.asp?Search=S&ID=459&Title=SMR00%20-%20Outpatient%20Attendance> (accessed 23 June 2020, date last accessed).
23. NHS Scotland. Scottish Ambulance Service. <http://www.scottishambulance.com/> (10 June 2020, date last accessed).
24. Docherty AB, Harrison EM, Green CA *et al.* Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ* 2020;369:m1985.
25. ISD Scotland Home. National Data Catalogue. *Rapid Preliminary Inpatient Data (RAPID)*. <https://www.ndc.scot.nhs.uk/National-Datasets/data.asp?SubID=37> (23 June 2020, date last accessed).
26. National Records of Scotland. *Vital Events – Deaths – Background Information*. <https://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/vital-events/deaths/deaths-background-information> (11 June 2020, date last accessed).
27. NHS Inform. Test and Protect. <https://www.nhsinform.scot/campaigns/test-and-protect> (02 July 2020, date last accessed).
28. National Records of Scotland. *Statistics and Data. Scotland's Census*. <https://www.nrscotland.gov.uk/statistics-and-data/census> (10 June 2020, date last accessed).
29. Public Health Scotland. *Search Criteria for Highest Risk Patients for Shielding (v4.0)*. 2020. https://hpspubsrepo.blob.core.windows.net/hps-website/nss/3008/documents/1_covid-19-search-criteria-highest-risk-patients.pdf (23 June 2020, date last accessed).
30. Public Health Scotland. *Data and Intelligence. Scottish Birth Record & Universal Newborn Hearing Screening*. <https://www.isdscotland.org/Products-and-Services/Scottish-Birth-Record/> (10 June 2020, date last accessed).
31. NHS Digital. *Birth Notification Service*. <https://digital.nhs.uk/services/birth-notification-service> (10 June 2020, date last accessed).
32. National Records of Scotland. *Vital Events – Births*. <https://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/vital-events/births> (10 June 2020, date last accessed).
33. National Records of Scotland. *Stillbirths and Infant Deaths*. <https://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/vital-events/deaths/deaths-background-information/stillbirths-and-infant-deaths> (10 June 2020, date last accessed).
34. NHS National Services Scotland. *National Data Catalogue. Notification of Abortion Statistics (AAS)*. <https://www.ndc.scot.nhs.uk/National-Datasets/data.asp?SubID=64> (10 June 2020, date last accessed).
35. Information Services Division (Public Health Scotland). *National Data Catalogue. Child Health Systems Programme – School (CHSP School)*. <https://www.ndc.scot.nhs.uk/National-Datasets/data.asp?ID=4&SubID=11> (11 June 2020, date last accessed).
36. Information Services Division (Public Health Scotland). *National Data Catalogue. Scottish Immunisation Recall System (SIRS)*. <https://www.ndc.scot.nhs.uk/National-Datasets/data.asp?ID=4&SubID=12> (11 June 2020, date last accessed).
37. Stock SJ, McAllister D, Vasileiou E *et al.* COVID-19 in Pregnancy in Scotland (COPS): protocol for an observational study using linked Scottish national data. *BMJ Open* 2020;10:e042813.
38. Clift AK, Keogh RH, Williamson E *et al.* Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. *BMJ* 2020;371:m3731.
39. Scottish Government. *Coronavirus (COVID-19): Shielding Advice and Support*. <https://www.gov.scot/publications/covid-shielding/> (June 23, 2020, date last accessed).
40. Air Quality in Scotland. Scotland's environment. <http://www.scottishairquality.scot/> (23 June 2020, date last accessed).